Xcout IntelSign inSubscribe

HIKMA PHARMACEUTICALS PLC

HIKPharmaceuticalsLondon, United Kingdom

Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.

Subscribe to see HIKMA PHARMACEUTICALS PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

HIKMA PHARMACEUTICALS PLC at a glance

HIKMA PHARMACEUTICALS PLC is a pharmaceuticals company headquartered in London, United Kingdom. It is publicly listed (HIK) with a market capitalisation of $4.6B. Xcout tracks 15 named people at HIKMA PHARMACEUTICALS PLC, including Khalid Nabilsi (Deputy CEO, North America and Europe).

Industry
Pharmaceuticals
Headquarters
London, United Kingdom
Market cap
$4.6B
Employees
9,400
Ticker
HIK

HIKMA PHARMACEUTICALS PLC leadership

  • Khalid NabilsiDeputy CEO, North America and Europe
  • Mazen DarwazehExecutive Vice Chairman and Deputy CEO, MENA
  • Said DarwazahChief Executive Officer
  • Hafrun FridriksdottirPresident, US and Chief R&D Officer
  • Hussein ArkhaghaChief People Officer
  • Bassam KanaanExecutive Vice President, Corporate Development and M&A

9 more named people on record for HIKMA PHARMACEUTICALS PLC, with roles, board committees and tenure — see the full roster →

HIKMA PHARMACEUTICALS PLC competitors

A few of HIKMA PHARMACEUTICALS PLC's closest competitors — see the full list of competitors and alternatives →

TEVATEVA · PharmaceuticalsTel Aviv, Israel
70% matchPublic

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

Market cap$45.8B
Employees37,000
TEVA competitors & alternatives →

Get HIKMA PHARMACEUTICALS PLC's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

HIKMA PHARMACEUTICALS PLC — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on HIKMA PHARMACEUTICALS PLC in Xcout Intel

  • 15 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →